Avantax Advisory Services Inc. Invests $269,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

Avantax Advisory Services Inc. purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 6,836 shares of the company's stock, valued at approximately $269,000.

Other hedge funds have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics during the third quarter valued at approximately $40,000. Highline Wealth Partners LLC bought a new position in shares of CRISPR Therapeutics in the 4th quarter worth approximately $39,000. Western Pacific Wealth Management LP raised its holdings in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after purchasing an additional 500 shares during the period. Spire Wealth Management raised its stake in CRISPR Therapeutics by 303.7% during the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after acquiring an additional 1,482 shares during the period. Finally, MCF Advisors LLC bought a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $80,000. 69.20% of the stock is owned by institutional investors.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now owns 8,263 shares of the company's stock, valued at approximately $350,516.46. This trade represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,381 shares of company stock valued at $1,608,243. Corporate insiders own 4.10% of the company's stock.

Remove Ads

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP traded down $1.05 during mid-day trading on Friday, reaching $36.99. 1,595,765 shares of the company traded hands, compared to its average volume of 1,551,646. The stock has a fifty day simple moving average of $43.10 and a 200-day simple moving average of $45.17. The firm has a market cap of $3.17 billion, a PE ratio of -8.46 and a beta of 1.77. CRISPR Therapeutics AG has a fifty-two week low of $36.52 and a fifty-two week high of $68.39.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CRSP. Stifel Nicolaus cut their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research report on Thursday, February 13th. Bank of America dropped their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Needham & Company LLC reiterated a "buy" rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, February 12th. HC Wainwright reissued a "buy" rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Finally, JMP Securities reiterated a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.